Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00700206 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by Telik.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00700206 is a Phase 2 study that has completed, run by Telik. The registered enrollment target is 86 participants.
The verdict
NCT00700206, a Phase 2 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This is a randomized, open label, multicenter, Phase 2 study comparing two dose schedules of Telintra in patients with Low or Intermediate-1 risk MDS. Patients at least 18 years of age presenting with histologically confirmed Low to Intermediate-1 risk MDS with documented significant cytopenia for at least two months by the IWG criteria are eligible.
Interventions
- DRUG Ezatiostat Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00700206
The ClinicalTrials.gov registry entry for NCT00700206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ezatiostat Hydrochloride is the first listed.
NCT00700206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00700206 about?
NCT00700206 is a clinical study titled "Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)". This is a randomized, open label, multicenter, Phase 2 study comparing two dose schedules of Telintra in patients with Low or Intermediate-1 risk MDS. Patients at least 18 years of age presenting with histologically confirmed Low to Intermediate-1 risk MDS with documented significant cytopenia for a...
What is the current status of trial NCT00700206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2008-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00700206?
The interventions under investigation include: Ezatiostat Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00700206?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.